Dr. Reddy's Confirms Voluntary Licensing Agreement with Gilead for HIV Drug
Dr Reddys Laboratories Ltd 路 Others (Uncategorized) 路 18 Sept 2026, 2:11 pm
Dr. Reddy's Confirms Voluntary Licensing Agreement with Gilead for HIV Drug Dr. Reddy鈥檚 Laboratories confirmed on 18th Sep'26 that it entered into a voluntary licensing agreement with Gilead Sciences for investigational once-yearly lenacapavir used in HIV prevention, validating media reports from 17th Sep'26. Clarifying a query from BSE regarding trading movement, the company stated the agreement does not constitute a material event requiring separate disclosure under Regulation 30 of SEBI Listing Regulations, confirming there is no unannounced material information or ongoing regulatory proceedings.
Original exchange filing (PDF)
More announcements from Dr Reddys Laboratories Ltd
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 路 14 Nov 2026
- Intimation of Analyst meet 路 11 Nov 2026
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 路 05 Nov 2026
- Allotment of Employee Stock options 路 04 Nov 2026
- Clarification - Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 路 04 Nov 2026
- The Exchange has sought Clarification from Dr Reddys Laboratories Ltd with reference to the media report appearing on https://www.firstpost.com dated November 03, 2026 (Link : https://www.firstpost.com/business/indias-dr-reddys-gets-us-nod-for-40-generic-hiv-prevention-shot-for-120-poorer-countries-14057224.html) .... 路 03 Nov 2026
- Transcript of Earnings call 路 30 Oct 2026
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 路 28 Oct 2026
